title: Total protein concentration and T-cell suppression activity of aqueous humour before and after penetrating keratoplasty.
abstract: OBJECTIVE
  We wished to determine whether immune privilege parameters assayed in aqueous humour (AqH) are relevant to the fate of penetrating keratoplasty (PK) in humans.
  
  
  METHODS
  AqH was collected in 28 patients before PK (prospective cohort), in 6 patients with no history of graft rejection undergoing cataract surgery after PK (acceptors), in another 6 patients undergoing treatment of an acute endothelial immune reaction (rejectors), and in 65 controls undergoing uncomplicated cataract extraction. AqH was tested for total protein concentration and the ability to suppress T-cell activation.
  
  
  RESULTS
  AqH protein concentrations of acceptors and rejectors post-PK were elevated (2.7 ± 0.8 and 2.7 ± 0.7 mg/ml, respectively) compared with pre-PK AqH level and cataract controls (1.0 ± 0.1 mg/ml, P = 0.01). All AqH samples suppressed T-cell activation, irrespective of source and timing of AqH removal.
  
  
  CONCLUSIONS
  Assays of immune privilege markers in AqH suggest that PK surgery may result in a sustained loss of integrity of the blood-aqueous barrier. Although trends were evident, values of immune privilege markers determined pre- and post-PK were not statistically significantly different between the study groups. However, further prospective studies determining additional immune privilege markers have to be conducted in order to find out whether these markers might serve as predictive parameters for immune reactions following PK.
authors.affiliation: Department of Ophthalmology, University of Louisville School of Medicine, Louisville, KY, USA.
authors.forename: J-S
authors.initials: JS
authors.lastname: Mo
authors.forename: P
authors.initials: P
authors.lastname: Maier
authors.forename: D
authors.initials: D
authors.lastname: Böhringer
authors.forename: H
authors.initials: H
authors.lastname: Reinshagen
authors.forename: R
authors.initials: R
authors.lastname: Sundmacher
authors.forename: T
authors.initials: T
authors.lastname: Reinhard
mesh_terms: D000869:Anterior Eye Segment / Q000276:immunology* / Q000473:pathology; D001082:Aqueous Humor / Q000276:immunology / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D018916:Blood-Aqueous Barrier / Q000276:immunology*; D015331:Cohort Studies; D005260:Female; D006084:Graft Rejection / Q000276:immunology; D006801:Humans; D015948:Keratoplasty, Penetrating / Q000009:adverse effects / Q000379:methods; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013601:T-Lymphocytes / Q000276:immunology*; D053781:Transforming Growth Factor beta2 / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D053781:Transforming Growth Factor beta2
references.citation: Eye (Lond). 1988;2 Suppl:S213-20
references.pmid: 3076149
references.citation: Arch Ophthalmol. 2002 Dec;120(12):1630-5
references.pmid: 12470135
references.citation: Mol Vis. 2007 Jul 17;13:1198-202
references.pmid: 17679942
references.citation: Mol Vis. 2011 Apr 25;17:1016-23
references.pmid: 21541263
references.citation: Klin Monbl Augenheilkd. 2001 Jun;218(6):412-7
references.pmid: 11488006
references.citation: Am J Transplant. 2008 Jul;8(7):1537-43
references.pmid: 18557741
references.citation: J Immunol. 2000 Feb 1;164(3):1185-92
references.pmid: 10640729
references.citation: Eye (Lond). 2008 Apr;22(4):569-75
references.pmid: 17975559
references.citation: Transpl Int. 2002 Mar;15(2-3):81-8
references.pmid: 11935164
references.citation: Invest Ophthalmol Vis Sci. 1991 Jul;32(8):2201-11
references.pmid: 2071334
references.citation: Arch Ophthalmol. 1994 Mar;112(3):354-8
references.pmid: 8129661
references.citation: Croat Med J. 2001 Dec;42(6):650-6
references.pmid: 11740849
references.citation: Cornea. 2003 Jul;22(5):413-9
references.pmid: 12827045
references.citation: Graefes Arch Clin Exp Ophthalmol. 2001 Feb;239(2):114-7
references.pmid: 11372539
references.citation: Doc Ophthalmol. 1999;99(2):171-82
references.pmid: 11097120
references.citation: Transplantation. 1992 Sep;54(3):463-7
references.pmid: 1412728
references.citation: Acta Ophthalmol Scand. 2004 Feb;82(1):13-8
references.pmid: 14738484
references.citation: Ophthalmology. 1998 Oct;105(10):1855-65
references.pmid: 9787355
references.citation: Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3326-31
references.pmid: 12882777
references.citation: Am J Ophthalmol. 1991 Jun 15;111(6):739-42
references.pmid: 2039046
references.citation: Klin Monbl Augenheilkd. 2003 Apr;220(4):253-6
references.pmid: 12695967
references.citation: Invest Ophthalmol Vis Sci. 1999 Dec;40(13):3152-9
references.pmid: 10586937
references.citation: Ophthalmic Res. 2000 Jul-Aug;32(4):157-64
references.pmid: 10828736
references.citation: Br J Ophthalmol. 2002 Jan;86(1):35-8
references.pmid: 11801500
references.citation: Ocul Immunol Inflamm. 2010 Jun;18(3):162-71
references.pmid: 20482389
references.citation: Eur J Immunol. 2001 Dec;31(12):3806-15
references.pmid: 11745402
references.citation: Trans Ophthalmol Soc U K. 1986;105 ( Pt 2):149-55
references.pmid: 2432702
references.citation: Acta Ophthalmol Scand. 2006 Dec;84(6):759-65
references.pmid: 17083534
references.citation: Transplantation. 1995 Jan 15;59(1):21-7
references.pmid: 7839424
references.citation: Mol Vis. 2010 Jan 15;16:53-60
references.pmid: 20090921